Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.51
USD
|
-5.62%
|
|
-15.17%
|
-43.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11.52
|
37.99
|
38.8
|
8.364
|
2.722
|
1.991
|
-
|
-
|
Enterprise Value (EV)
1 |
11.52
|
37.99
|
38.8
|
8.364
|
2.722
|
1.991
|
1.991
|
1.991
|
P/E ratio
|
-1.34
x
|
-2.28
x
|
-1.82
x
|
-0.35
x
|
-0.1
x
|
-0.11
x
|
-0.06
x
|
0.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
6.48
x
|
-
|
-
|
0.04
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
6.48
x
|
-
|
-
|
0.04
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
57.3
|
324
|
665
|
836
|
1,019
|
1,318
|
-
|
-
|
Reference price
2 |
201.0
|
117.1
|
58.35
|
10.00
|
2.670
|
1.510
|
1.510
|
1.510
|
Announcement Date
|
2/26/20
|
2/25/21
|
3/28/22
|
3/6/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.42
|
-
|
-
|
55.99
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.682
|
-10.64
|
-22.94
|
-27.66
|
-25.45
|
-16.26
|
-84.48
|
25.11
|
Operating Margin
|
-
|
-
|
-
|
-
|
-6,060.24%
|
-
|
-
|
44.84%
|
Earnings before Tax (EBT)
1 |
-9.126
|
-9.681
|
-22.73
|
-25.92
|
-25.55
|
-26.46
|
-28.57
|
25.48
|
Net income
1 |
-8.03
|
-12.4
|
-19.09
|
-21.4
|
-22.76
|
-23.72
|
-26.67
|
24.83
|
Net margin
|
-
|
-
|
-
|
-
|
-5,418.1%
|
-
|
-
|
44.34%
|
EPS
2 |
-150.0
|
-51.30
|
-32.10
|
-28.50
|
-26.75
|
-13.38
|
-24.37
|
3.000
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
3/28/22
|
3/6/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.373
|
0.016
|
0.031
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.998
|
-6.534
|
-6.559
|
-5.785
|
-6.467
|
-8.845
|
-7.319
|
-5.929
|
-6.845
|
-5.36
|
-4.538
|
-4.084
|
-3.878
|
-3.759
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,589.54%
|
-42,781.25%
|
-17,290.32%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.985
|
-6.491
|
-5.246
|
-5.559
|
-6.11
|
-9
|
-7.124
|
-6.034
|
-6.699
|
-5.693
|
-6.493
|
-6.607
|
-6.723
|
-6.841
|
Net income
1 |
-5.037
|
-5.344
|
-4.158
|
-4.625
|
-5.146
|
-7.469
|
-5.854
|
-5.498
|
-6.147
|
-5.321
|
-5.993
|
-6.107
|
-6.223
|
-6.341
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,473.99%
|
-38,418.75%
|
-17,164.52%
|
-
|
-
|
-
|
-
|
EPS
2 |
-8.100
|
-8.100
|
-6.300
|
-6.900
|
-6.300
|
-9.000
|
-7.050
|
-6.600
|
-7.350
|
-6.230
|
-4.560
|
-3.440
|
-3.200
|
-2.590
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/28/22
|
5/11/22
|
8/10/22
|
11/9/22
|
3/6/23
|
5/11/23
|
8/9/23
|
11/13/23
|
3/19/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
3/28/22
|
3/6/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
1.51
USD Average target price
163
USD Spread / Average Target +10,694.70% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.45% | 1.99M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|